Outlook 2023: The Pharma Rollercoaster Shows No Signs Of Slowing Down

What will 2023 bring as the industry faces one of the toughest periods in the last decade? In Vivo asked three industry experts for their views.

Rollercoaster
• Source: Shutterstock

The biopharma train is riding into unfamiliar territory. An era shift to high-cost capital from low-cost capital, macro-economic considerations from the intense and unpredictable geopolitical situation in eastern Europe, worldwide inflation, and a continued flirt with global recession could push companies off course, while the swirling myriad of industry issues such as the competition for talent, the politicization of drug pricing in the US, leveling up diversity in clinical trials, and increasing pressure to prove commitment to ESG (Environmental, Social and Governance) issues could make the horizon difficult to see with the required clarity.

And how could we forget the patent cliff? Over the course of the next six years, the patent cliff looms...

More from Outlook Archive

More from Outlook